ArticleAntioxidants & redox signaling2013
Redox pioneer: Professor Stuart A. Lipton.
Article in Antioxidants & redox signaling, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
[Figure: see text] Stuart A. Lipton, M.D., Ph.D. is recognized here as a Redox Pioneer because of his publication of four articles that have been cited more than 1000 times, and 96 reports which have been cited more than 100 times. In the redox field, Dr. Lipton is best known for his work on the regulation by S-nitrosylation of the NMDA-subtype of neuronal glutamate receptor, which provided early evidence for in situ regulation of protein activity by S-nitrosylation and a prototypic model of allosteric control by this post-translational modification. Over the past several years, Lipton's group has pioneered the discovery of aberrant protein nitrosylation that may contribute to a number of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (Lou Gehrig's disease). In particular, the phenotypic effects of rare genetic mutations may be understood to be enhanced or mimicked by nitrosative (and oxidative) modifications of cysteines and thereby help explain common sporadic forms of disease. Thus, Lipton has contributed in a major way to the understanding that nitrosative stress may result from modifications of specific proteins and may operate in conjunction with genetic mutation to create disease phenotype. Lipton (collaborating with Jonathan S. Stamler) has also employed the concept of targeted S-nitrosylation to produce novel neuroprotective drugs that act at allosteric sites in the NMDA receptor. Lipton has won a number of awards, including the Ernst Jung Prize in Medicine, and is an elected fellow of the AAAS. Antioxid. Redox Signal. 19, 757-764.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.